Health Press Release – Newsletter for February 10, 2011

ALQAEM International to Make Noninvasive Glucose Monitor Available in the Region

DUBAI, United Arab Emirates, February 10, 2011 – The Health Care Division of ALQAEM International FZE, the
exclusive master distributor for the M.E.N.A. region of the UFIT(R)
noninvasive medical device created by Biosign Technologies Inc. of Canada, is
pleased to announce that it has placed orders for delivery this quarter and
will begin a limited release in March …. Source  : ALQAEM International to Make Noninvasive Glucose Monitor Available in the Region.

Oncos Therapeutics Increases Clinical Momentum With Appointment of Chief Medical Officer

HELSINKI, February 9, 2011 – Oncos Therapeutics, a biotech company developing novel cancer
therapeutics based on its next generation oncolytic viruses, announced today
the appointment of Dr. Mikael von Euler, MD, PhD, FFPM, as Chief Medical
Officer. Earlier this year, the Company announced the appointments of Dr.
Jonathan Knowles and Dr. Robert Burns to its Board of Directors.

…. Source article  : Oncos Therapeutics Increases Clinical Momentum With Appointment of Chief Medical Officer.

MarketsandMarkets: Global Injectable Drug Delivery Market To Be Worth $29,981 Million By 2015

DALLAS, February 9, 2011 – According to a new market research report, 'Global Injectable Drug
Delivery Market (2010 – 2015)', published by MarketsandMarkets
(www.marketsandmarkets.com), the global injectable drug delivery
market shows a significant growth potential and is expected to rise from
$14,994 million in 2009 to $29,981 million in 2015 at a CAGR of 12.3% during
2010-2015.

…. Original article  : MarketsandMarkets: Global Injectable Drug Delivery Market To Be Worth $29,981 Million By 2015.

Frost & Sullivan Technology Innovation Award Conferred on AQTIS Medical BV for its Pioneering Ellanse(TM)

LONDON, February 9, 2011 – The 2011 Frost & Sullivan European Technology Innovation of the Year
Award in Dermal Fillers is presented to AQTIS Medical BV in recognition of
its pioneering Ellanse(TM).

(Logo: photos.prnewswire.com/prnh/20081117/FSLOGO)
"This novel range of dermal fillers supports safe and cost-effective
treatments in aesthetic medicine and surgery, through … Read more >>.

Stop Proofreading – Start Bunnying! Schlafender Hase Releases New Version of the Text Verification Tool (TVT)

FRANKFURT, Germany, February 9, 2011 – Schlafender Hase ("sleeping hare") GmbH is not just changing the way the
pharmaceutical industry does proofreading. It is changing the word for
proofreading. "Have you 'bunnied' your text? That's the way one of our top US
customers asks if the proofreading process has been done," said Willie
Schnaubelt, managing director of Schlafender [..] Read the original article: here.

Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial

MOUNTAIN VIEW, California, February 9, 2011 – Concentric Medical, Inc. today announced that the first patients were
enrolled in TREVO 2 (Thrombectomy REvascularization of large Vessel
Occlusions) at Oregon Health & Science University in Portland, Oregon and at
Capital Health in Trenton, New Jersey. Oregon Health & Science enrolled the
first patient in TREVO 2 and Capital Health …. Original article on Gaea Times at  : Concentric Medical Announces First Patients Enrolled In TREVO 2 Clinical Trial.

ReportsnReports – The European Minimally Invasive Spinal Implant Markets Are Expected Exceed EUR90 Million By 2017

DALLAS, February 9, 2011 – ReportsnReports announces it will carry European Markets for Minimally
Invasive Spinal Devices 2011 Research Report in its store.

Browse the complete Report on:
www.reportsnreports.com/reports/59358-european-markets-for-minimally-i
nvasive-spinal-devices-2011.html
Search More Then 60000 Market Research Reports at
www.reportsnreports.com/
The European minimally invasive spinal implant markets are expected
exceed EUR90 …. Original source  : ReportsnReports – The European Minimally Invasive Spinal Implant Markets Are Expected Exceed EUR90 Million By 2017.

Syngenta CEO Interviewed on New Strategy and 2010 Results

LONDON, February 9, 2011 – Syngenta, the world's largest agribusiness, says the decision to
integrate its Crop Protection and Seeds business would take the operations to
a "higher level of performance".

Earlier today in an interview with financial news website
www.cantos.com, Syngenta CEO Mike Mack said the first stages of the
integration would be complete …. Source  : Syngenta CEO Interviewed on New Strategy and 2010 Results.

Torchmark Corporation Reports Fourth Quarter and Year-End 2010 Results

MCKINNEY, Texas, February 9, 2011 – Torchmark Corporation (NYSE: TMK) reported today that for the quarter
ended December 31, 2010, net income was $1.91 per share, compared with $1.36
per share for the year-ago quarter. Net operating income for the quarter was
$1.68 per share, compared with $1.47 per share for the year-ago quarter.

… Read : Torchmark Corporation Reports Fourth Quarter and Year-End 2010 Results.

Zebinix, Novel Once-Daily Anti-Epileptic Treatment, Launches in Spain

HATFIELD, England, February 10, 2011 – Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for
adults with partial-onset seizures, with or without secondary generalisation
(where the seizure spreads to both sides of the brain), has been launched
today in Spain by Eisai and BIAL in a co-promotion.

In 2009, the European Commission approved Zebinix based …. Source  : Gaea News Network.

Mobily Launches Mobile Baby(TM) Service for Transmitting Sonograms to Subscribers’ Mobile Phones

Mobily is the first mobile operator worldwide enabling parents to receive and send ultrasound scans wirelessly to their friends, family and loved ones

SAN DIEGO and RIYADH, Saudi Arabia, February 10, 2011 – Saudi Arabian telecommunications company Mobily and Great Connection
Inc., creator of the innovative Mobile Baby(TM) service, announced the launch
of the first mobile medical …. Original article  : Mobily Launches Mobile Baby(TM) Service for Transmitting Sonograms to Subscribers' Mobile Phones.